News

VAXEAL PARTICIPATED IN THE IPROVE ROADMAP

Vaxeal participated in the IProve Roadmap to foster vaccine innovation launched in European Parliament

IPROVE roadmap informs strategic decisions on the priorities for future vaccine investment

Brussels, 16 March 2016: The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) – financed under the EU 7th Framework Programme (FP7) – today launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years.

The roadmap, which is the first of its kind, was launched during a special European Parliament event that took place on the 16th of March and was hosted by MEPs Francoise Grossetête, Cristian-Silviu Busoi and Markus Ferber. Key opinion leaders in the field of vaccine research and development attended the event including representatives from the European Commission, the European Parliament, European Union Member States and a broad representation of the vaccines community including academia, industry, civil society and regulatory bodies.

The IPROVE roadmap will inform strategic decisions on the priorities for future vaccine investment in innovation and technological development at European Union and individual Member State level. Through a bottom-up approach involving all key stakeholders in the European vaccine field, the strategy aims to overcome fragmentation and remove bottlenecks to translation of breakthrough research into innovative vaccines.

Following a two year consultation period, the plan covers the critical areas of intervention relevant to the entire innovation value chain, defines priorities and makes recommendations to support and accelerate research in vaccines, to help steer European competitiveness in this field for the delivery and benefit of innovative prophylactic and therapeutic vaccines.

The IPROVE roadmap focuses on seven main thematic topics of consultation;

• Vaccine R&D
• Therapeutic Vaccines
• Production and Manufacturing
• Infrastructures
• Vaccine SME needs
• Training
• Communications and Acceptance of Vaccination.

“I have been delighted to be involved in this great work, and a main author of the IProve roadmap. Today, Therapeutic Vaccines and SMEs are fully integrated in the EU vaccine innovation strategy. I consider the event in European Parliament as a kick-off meeting for future concrete actions. We now have to prioritize and to implement the roadmap. I am extremely confident that EU-based vaccine SMEs will be at center stage of the EU innovation strategy in the coming years”, said Ahmed Bouzidi, CEO of Vaxeal. “We must strenghten the EU integrated vaccine research, involving all EU vaccine stakeholders, to maintain Europe’s leading position, and to assure patients’s access to novel generations of preventive and therapeutic vaccines”, added the CEO of Vaxeal.

You can read or download the roadmap document at: www.iprove-roadmap.eu

About Vaxeal: Created in 2009, Vaxeal Holding SA is an SME headquartered in Vevey (Switzerland). The company, in partnership with leading International Research Institutes, is developing fixed combinations of T-cell-based therapeutic vaccines and immuno-modulatory drugs for the treatment of cancers. The initial programs have reached the completion of pre-clinical stage in major disease segments, and are expected to enter into clinical trials soon. Vaxeal is member of Vaccines Europe, and the European Biopharmaceutical Enterprises. The company received a special MIT award for “its remarkable breakthrough in the field of vaccines”. www.vaxeal.net

About IProve: The IPROVE consortium comprises four renowned organisations in the vaccine field in Europe: Vaccines Europe (VE), a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA) representing all major research-based vaccine global companies as well SMEs operating in Europe; the European Vaccine Initiative (EVI), a leading European Product Development Partnership supporting the development of effective, accessible, and affordable vaccines against diseases of poverty; the Sclavo Vaccines Association (SVA), a non-profit association whose main objective is to promote vaccine research targeted towards the discovery and study of advanced immunisation technologies; and EATRIS, a European consortium of academic institutions of excellence in translational research, working together to advance candidates into clinical development. www.iprove-eu.eu